Strong growth, margin pressure; capex cycle ends, ROCE climb begins

Delivered ₹1,165.5 Cr. Volume 9% + pricing 37% = 46% growth. Verified.

EBITDA ₹147 Cr vs ₹116 Cr prior year = 26.7% growth. Port headwind cited credibly.

Margin fell 190 bps. EBITDA/kg up 15% on 9% volume growth shows underlying improvement. Explanation sound.

PAT growth 25.4% vs revenue 46% - indeed moderate leverage. Depreciation/interest headwind evident.

Specialty film margins held ₹63/kg (supported). BOPET sharp drop ₹18→₹9/kg is structural concern (30k MT segment).

Numbers cited but not cross-verified. Management detailed these; assume disclosed accuracy.

Plastech turned EBITDA positive Q1, Specialty Chemicals 25% margin. Capex investment of ₹1,200 Cr over 3 years treated as near-complete.

Mgmt now signals ₹400-500 Cr target achievable by FY29 (vs prior FY30 guidance) on 34% Q1 growth. Meaningful upgrade.

BOPET gross margin ₹9/kg (Jun) vs ₹18/kg (Mar-26) vs ₹13/kg (Jun-25) is new low. Anti-dumping duty expected to help, but no recovery timeline given. Structural headwind vs prior optimism.

13% export volume loss and in-transit buildup newly disclosed. Expected to recover in Q2 as situation normalizes. Temporary but material drag.

ROCE 11% → 15-20% target over 12-24 months reaffirmed. No acceleration. Depends on EBITDA growth + capex discipline; both in flight.

Multiple levers: 15% spare capacity in film; volume growth 20% FY27; specialty sales growth 12%; US growth 25-30%; new businesses 60% growth. All existing businesses have spare capacity or minimal capex for expansion.

Q1 alone: synthetic paper film, PVC-free films, anti-fog BOPET lidding. 6 patents granted, 11 in pipeline. Specialty margins held ₹63/kg (vs base ₹20-30/kg). All incremental capex to specialty assets.

Revenue +46% from 9% volume + raw material prices. Per-kg contribution improved across all categories. EBITDA up 26% on 9% volume = EBITDA/kg +15%. This is the real operating story; margin % compression is accounting effect of pass-through business.

BOPP largely flat ex-stock gains. BOPET margins marginally down but anti-dumping duty recently levied should help recovery. India over-capacity in BOPET, expected to correct coming quarters. Cosmo shifting commodity BOPET to specialty BOPET.

Plastech 58% growth; robust FMCG demand. With minimal capex, adding 50% capacity. FY26: ₹100 Cr; FY27: ₹150-160 Cr; FY28: ₹200+ Cr. Business now at 7% EBITDA (excl. incentives 10%+), margin improvement on scale.

Film: 85%. Specialty Chemicals: 15-20% spare capacity. Plastech: at capacity, adding 50% more. Film specialty can reach 90% without significant capex via mix shift.

Gross margins ~50%. Quarter-on-quarter EBITDA loss % declining. Monthly run rate ₹100 Cr annualized. Need to scale to certain level before Zigly makes money. Couple more years to breakeven. Breakeven likely at ₹250 Cr revenue.

Deliberate investment phase. 4 new retail centers, 2 hospital acquisitions, 20+ private label launches. EBIT margin improved 82%→69%. Unit economics strong, gross margin 47%, services 64% of revenue, private label +105% YoY, 30% repeat customers. Shift to services and private labels (highest margin, fastest growing). 47 centers, 29k customers, ₹100 Cr GMV annualized run rate in 22% growing market.

Each business has separate team, so no bandwidth issue. Cosmo Consumer made graphene/ceramic coatings (first in India, currently all imported). Domestic focus: build strong brand 3-4 years. Export: initially white-label, gradually own brand. 150 dealers, 100+ cities, 4 new PPF variants, high-performance carbon pigment window films.

80% internal but external business also growing. Costing on third-party arm's length basis. Margins from innovation, not internal transfer pricing. Medium-term: third-party growth faster, should balance internal and external.

Good likelihood to surpass target by FY29 itself (one year earlier). No explicit capacity constraint signaled.

Both. Last 9 months: ₹70 Cr net debt reduction despite ₹85 Cr WC increase. Current: ₹1,166 Cr net debt (2.3x EBITDA). Next 2 years: containing significant capex, ROCE/EBITDA improvement, expect ₹400-500 Cr debt reduction. Already moved 2.6x → 2.3x despite WC headwind.

Renewable power savings yet to kick in. Entered private purchase power agreements (2 projects), both yet to commence. One expected Q3 FY27, another Q1 FY28. Nothing in Q1 FY27.

Domestic market growing well (4.5x YoY last year, 3x+ this year). Global market takes time. 150 dealers, 100+ cities, 4 PPF variants. Hard to project long-term numbers without European/American market traction. Currently 25% margins (up from 15-17%), expect 35-40% gross margins with scaling.

Last year US line started mid-Q1. This year: in-transit volume buildup due to port disturbances (not booked as sales until bill of lading). One line under maintenance couple thousand tons. Expected recovery in Q2 as port normalizes.

No capacity ceiling for specialty because target is to keep improving mix. Already 61% current (highest 5 qtrs). Objective: 70%. From 85% utilization, meaningful headroom. No need for new capacity; mix shift within existing assets.

All businesses have potential ₹500 Cr to ₹1000 Cr. Achievable over 5-6 years.

Objective: 20%+ ROCE. Currently started improving. At ₹300-350 Cr revenue, expect 15%+ ROCE. Just turned profitable Q1; looking to reach double-digit profitability by end FY27, grow from there.

Supported by core film business 9% volume capacity, new businesses 60% growth, US 25-30% benefit post-tariff. Q1 46% sets up achievable 20% for year if normalization occurs.

Q1 delivers: Specialty Chemicals 34%, Plastech 58%, Zigly 70%, Cosmo Consumer 3x+. Scaling all four simultaneously is ambitious but traction visible.

Duty relief received, but Q1 showed 13% export volume loss to port congestion. Realization depends on normalcy in logistics; vulnerability to geopolitical tariff changes remains.

Clear strategic push; 6 new products launched Q1, 11 patents in pipeline. Needs continued market acceptance and operational execution; achievable but not guaranteed.

Management claims margins sustainable (volume growth, specialty mix, US tariff benefit, new business EBITDA positive). But Q1 margin compression (12.6% vs 14.5% YoY) and BOPET halving (₹9/kg) show headwinds outweighing tailwinds near-term.

Specialty margins held ₹63/kg for 5 quarters; management credibly cites product innovation and differentiation premium. Higher mix (toward 70-90%) would lift overall margins.

Strategic shift from build to harvest phase. Plastech adding 50% capacity with 'minimal capex'. Film business targeting 90% specialty without new capex, mix shift. Aligns with ROCE improvement priority.

Two PPA projects in flight; timing stated. Execution risk on grid/renewable timelines. If slips, near-term cost savings will miss.

46% revenue growth from 9% volume + 37% pricing. Pass-through business has margin expansion capped. If crude prices fall or demand softens, pricing power erodes and margins recompress.

BOPET 30k MT capacity (12% of total) faces structural margin pressure. ₹9/kg Q1 vs ₹18/kg prior quarter and ₹13/kg YoY is a 50% YoY decline. India over-capacity cited but no clear timeline for correction.

Port congestion reduced export volumes 13% Q1. US accounts for material export revenue; tariff duty reversal provided USD 7 Mn refund, but future tariff escalation is political risk.

Zigly loss widened ₹10 Cr → ₹15 Cr Q1 despite 70% YoY growth. Breakeven target ₹250 Cr revenue (2-3 year timeline) may slip if brand investment accelerates. Cosmo Consumer near breakeven but still investing.

ROCE 11% is low for a specialty materials company with ₹1,200 Cr capex invested. Target 15-20% in 12-24 months requires EBITDA growth + asset sweating without further capex. If macro softens or new capex emerges, ROCE stays depressed longer.